Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

23.50 -0.49 (-2.04%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Volume	1,677,444
Open	24.24
Bid (Size)	23.05 (500)
Ask (Size)	24.54 (800)
Prev. Close	23.99
Today's Range	23.00 - 24.43
52wk Range	8.580 - 25.16
Shares Outstanding	69,484,053
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

Today 9:29 EDT

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

Today 9:18 EDT

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Performance

YTD	+10.3%	+10.3%
1 Month	+10.2%	+10.2%
3 Month	+15.1%	+15.1%
6 Month	+43.6%	+43.6%
1 Year	+79.1%	+79.1%

More News

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 04, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings Outlook ↗

October 31, 2025

Via Benzinga

Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Via The Motley Fool

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation in March Investor Conferences

February 23, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

February 19, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

February 05, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 04, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

January 07, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

December 12, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

December 08, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

December 01, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?

Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market

What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?

The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 23.50

When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 03/13/26 04:00 PM ET

What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.63B

How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?

Syndax Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.